Survival from Cervical Cancer Diagnosed Aged 20-29 Years by Age at First Invitation to Screening in England: Population-Based Study.

cancer intelligence cervical cancer cervical screening early diagnosis hazard ratios micro-invasion mortality overdiagnosis screen-detected survival trends young women

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
28 Jul 2020
Historique:
received: 10 06 2020
revised: 09 07 2020
accepted: 16 07 2020
entrez: 1 8 2020
pubmed: 1 8 2020
medline: 1 8 2020
Statut: epublish

Résumé

Age at which women are first invited to attend cervical screening in England has changed twice: in 2004, women under 25 years were no longer invited; and in 2012, first invitations were sent six months earlier (at age 24.5 years). Concomitantly, a dramatic increase in screen-detected cervical cancer was observed, and their survival had not been documented. Diagnoses of invasive cervical cancer at ages 20-29 years in 2006-2016 in England were followed until the end of 2018 for deaths. We estimated 8-year overall survival (OS) by International Federation of Gynecology and Obstetrics (FIGO) stage and age at first screening invitation. Overall and relative survival for stage IA cervical cancer for women diagnosed aged 20-29 years in England (

Identifiants

pubmed: 32731340
pii: cancers12082079
doi: 10.3390/cancers12082079
pmc: PMC7463626
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Cancer Research UK
ID : C8162/A27047
Pays : United Kingdom

Références

Int J Epidemiol. 2020 Feb 1;49(1):16-16h
pubmed: 31120104
Int J Cancer. 2020 Mar 1;146(5):1230-1240
pubmed: 31107987
J Obstet Gynaecol Can. 2012 Dec;34(12):1167-1176
pubmed: 23231799
Acta Oncol. 2012 Sep;51(7):915-21
pubmed: 22928692
J Med Screen. 2012 Jun;19(2):89-93
pubmed: 22653575
Prev Med. 2018 Feb;107:21-28
pubmed: 29247658

Auteurs

Alejandra Castanon (A)

School of Cancer & Pharmaceutical Sciences, Innovation Hub, Guys Cancer Centre, Guys Hospital, London SE1 9RT, UK.

Daniela Tataru (D)

National Cancer Registration and Analysis Service, Public Health England, London SE1 8UG, UK.

Peter Sasieni (P)

School of Cancer & Pharmaceutical Sciences, Innovation Hub, Guys Cancer Centre, Guys Hospital, London SE1 9RT, UK.

Classifications MeSH